Series 7: The Last Mile of Brain Science

SERIES 7: THE LAST MILE OF BRAIN SCIENCE

AUTHOR: KJ Lavan

We Are Democratizing Detection Before Democratizing Care

The next crisis in #Alzheimer’s disease may not be a shortage of scientific breakthroughs.

It may be a shortage of systems capable of using them.

The science is advancing rapidly.

Lecanemab and donanemab can slow progression in appropriately selected people with early Alzheimer’s disease. But these therapies require confirmation of amyloid pathology, specialist evaluation, infusions, MRI monitoring and management of amyloid-related imaging abnormalities. (U.S. Food and Drug Administration⁠)

In July 2026, the FDA approved an at-home starting dose of lecanemab—another step toward making treatment more accessible. 

Yet, moving administration closer to the home does not eliminate the need for diagnosis, patient selection, safety surveillance and coordinated clinical oversight.

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment (U.S. Food and Drug Administration⁠)

Diagnostics are also crossing a threshold.

The FDA-cleared Lumipulse blood test measures the plasma p-tau217 to amyloid-beta 1-42 ratio to help identify Alzheimer’s-associated amyloid pathology in cognitively impaired adults. But false-positive and false-negative results remain possible, meaning a blood test is not a stand-alone diagnosis.

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease (U.S. Food and Drug Administration⁠)

The frontier is moving earlier still.

A July 2026 JAMA study found that cognitively unimpaired adults with very high p-tau217 levels faced an estimated 38% risk of cognitive impairment within five years.

https://jamanetwork.com/journals/jama/article-abstract/2851720 (JAMA Network⁠)

Dried-blood-spot research could make biomarker collection even more decentralized—potentially reaching people far beyond specialist clinics.

https://www.nature.com/articles/s41591-025-04080-0 (Nature⁠)

This sounds like democratization.

But detection without delivery is not democratization.

It is diagnostic exposure.

What happens when millions more people can be identified?

BUT, the system cannot provide:

• timely specialist consultations

• confirmatory testing

• genetic counseling

• MRI and infusion capacity

• prevention and risk-reduction services

• treatment financing

• caregiver support

• culturally appropriate longitudinal care

Blood biomarkers could shorten the road to diagnosis while simultaneously creating a traffic jam at every point after it.

Real-world studies suggest anti-amyloid therapies can be deployed through structured clinical pathways. 

But “feasible in an organized center” is not the same as scalable across fragmented health systems, rural communities or lower-resource countries. (Alzheimer’s & Dementia⁠)

And there is a deeper economic question.

A 2026 analysis estimated that scaling lecanemab across the United States could produce approximately 180,000 quality-adjusted life-years at a cost of $39.5 billion, while a collaborative dementia-care model was projected to produce substantially greater population benefit. The lesson is not that therapeutics are unimportant. It is that medicines and scalable care infrastructure must advance together. (Alzheimer’s & Dementia⁠)

The next competitive advantage will not belong only to the country that discovers the best biomarker or therapy.

It will belong to the country that builds the strongest translation system around it.

The real innovation stack is:

Discovery → Validation → Diagnosis → Treatment → Monitoring → Care → Prevention → Population Impact

MOST systems are investing heavily in the first three layers.

The greatest human and economic value may depend on everything that follows.

Scientific innovation is accelerating.

🔑  But unless institutional absorption capacity accelerates with it, we will produce more breakthroughs

…WITHOUT producing proportionate impact.

That is the last mile of brain science.

And it may be the most important infrastructure challenge of the Cognitive Resilience Economy.

AUTHOR: KJ Lavan

#McKinseyHealthInstitute #WorldHealthOrganization #AlzheimersDiseaseInternational #GlobalCEOInitiativeonAlzheimer’sDisease #WorldDementiaCouncil #UnitedNations #AlzheimersAssociation #AlzheimersDrugDiscoveryFoundation #DavosAlzheimersCollaborative #UsAgainstAlzheimers #BrainMatrixAlliance #PaolaBarbarino